Furthermore, a high ApoB/ApoA-I, which is considered atherogenic, may contribute to tumor necrosis34, 35; 2) A research group found that ApoA-I and its mimetic peptides can reduce the viability and proliferation of ovarian carcinoma cells in vivo and in vitro36; 3) Additionally, some studies indicated that apolipoprotein can initiate cellular signal transduction and promote antitumor drug delivery14, 37, 38; 4) In several studies, ApoA-I potently suppressed tumor growth and metastasis by both innate and adaptive immune processes12, 13, 39, 40. This evidence concerns the gene APOA1 and ovarian carcinoma.